AT2221, ATB200
ATB200-07
Phase 3 small_molecule active
Quick answer
AT2221, ATB200 for Adult Subjects With Late Onset Pompe Disease (LOPD) is a Phase 3 program (small_molecule) at Amicus Therapeutics Europe Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amicus Therapeutics Europe Limited
- Indication
- Adult Subjects With Late Onset Pompe Disease (LOPD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active